Authors
Latest:
Is there a difference between MD and DO in urology?"Osteopathic urologists were more likely to work in private practice (58.4% vs 49.8%; P = .038) and in rural/nonmetropolitan areas (16.2% vs 8.7%; P = .002)," write the authors.
Latest:
Mohit Khera, MD, on the impact of penile prosthesis implant on mental health“What [we] found was that those men who received a penile implant had a significant reduction in depression and psychological distress," says Mohit Khera, MD, MBA, MPH.
Latest:
Reimplantation of Tibial Nerve Stimulation Device (eCoin)OAB experts share their experience with reimplantation of a tibial nerve stimulation device (eCoin).
Latest:
18F-flotufolastat PET alters treatment approach for nearly 90% of patients with recurrent prostate cancer“Treatment based on visualization of 18F-flotufolastat–avid lesions may facilitate optimal targeting of recurrence sites and avoid futile salvage therapy,” said Przemyslaw Twardowski, MD.
Latest:
Is there a difference between MD and DO in urology?"Osteopathic urologists were more likely to work in private practice (58.4% vs 49.8%; P = .038) and in rural/nonmetropolitan areas (16.2% vs 8.7%; P = .002)," write the authors.
Latest:
Future Directions in mCRPCPanelists discuss how the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) is rapidly evolving through advancements in precision medicine and novel therapies, while emphasizing the importance of ongoing education for community oncologists to stay updated on these changes.
Latest:
Physician highlights AI’s potential to improve practice efficiency and alleviate burnoutArtificial intelligence can help curate, decipher, and contextualize the enormous and growing amount of digital data that now comprises a patient’s electronic health record, writes Nele Jessel, MD.
Latest:
How the SECURE Act affects inherited IRAsLegislation sets 10-year withdrawal window for nonspouse beneficiaries.
Latest:
The evolving role of microRNAs in testicular cancer management"This brief review captures the evolving role of miRNAs, focusing on their clinical relevance and implications as well as future directions for more effective targeted therapeutic interventions," write the authors.
Latest:
CLEAR trial analyses reaffirm benefit of lenvatinib/pembrolizumab in aRCC"The updated results from CLEAR trial confirming that the amount of tumor shrinkage correlates with prognosis through overall survival, PFS, as well as through IMDC prognostic scoring should add further weight to lenvatinib and pembrolizumab being a go-to standard of care in this setting," says Thomas E. Hutson, DO, PharmD.
Latest:
FDA, French ANSM greenlight pivotal trial of UroActive smart implant for male SUIThe SOPHIA2 trial will assess the safety and efficacy of the UroActive implant in men with SUI.
Latest:
Cleveland Clinic is First to Use Wireless, Catheter-Free Device to Monitor Bladder Dysfunction in PatientsGlean™ Urodynamics System developed by Bright Uro based on foundational technology created at Cleveland Clinic; Device received FDA clearance earlier this year
Latest:
Future Directions for Imaging and Biopsy in Prostate CancerThe panel offers key takeaways on the evolving landscape for imaging and biopsy in prostate cancer, highlighting the role for fusion-guided biopsy in the diagnosis and management of prostate cancer.
Latest:
Margaret Knoedler, MD, on robot-assisted mini-PCNL with the MONARCH PlatformMargaret A. Knoedler, MD, discusses the advantages of using the MONARCH platform for mini-PCNL.
Latest:
Artificial intelligence is the new ghost author in urological research“Although the future of AI within science is uncertain, disclosure of the use of AI is an excellent first step to balance academic integrity with disruptive innovation,” the authors write.
Latest:
Nivolumab/Cabozantinib combo continues to show HRQOL benefit in renal cell carcinomaLong-term follow-up from the CheckMate 9ER trial continued to show that first-line treatment with nivolumab plus cabozantinib was associated with a health-related quality-of-life benefit over treatment with sunitinib in patients with advanced renal cell carcinoma .
Latest:
Thomas Mueller, MD, on the removal of residual stone fragments“The 1 main assumption that we've been very wrong on although we've had the data for a long period of time, [is that] although we assume that the stone fragments are small enough to pass, oftentimes they don't,” says Thomas Mueller, MD.
Latest:
Suffering from Bladder or Pelvic Floor Issues? Here’s How a Urogynecologist Can HelpUrogynecologists focus on female pelvic medicine and reconstructive surgery, handling issues related to the pelvic floor and bladder.
Latest:
Integrating ctDNA in NMIBC: Promise and practical challengesFrom a practical standpoint, integrating ctDNA into clinical practice poses challenges.
Latest:
Key Trials on PARP Inhibitor Combinations in Metastatic Prostate Cancer: Efficacy and Future ConsiderationsPanelists discuss how the increased use of androgen receptor–targeted therapy in clinical practice may impact the effectiveness of PARP inhibitor combinations like talazoparib in the TALAPRO-2 study, while also addressing safety concerns, potential differences in trial populations, and the need for future studies to optimize treatment approaches for various metastatic prostate cancer patient subgroups.
Latest:
Michelle Sheng, MD, on strategies to improve female representation in urology“I think promoting women in leadership positions, promoting mentorship for women applicants and women already in this field, and working on policy changes are the top 3,” says Michelle S. Sheng, MD.
Latest:
Novel FGFR2/3 inhibitor shows promise in solid tumors, including bladder cancerThe novel agent ABSK061 approached a response rate of 40% in patients with advanced solid tumors harboring FGFR2/3 alterations.
Latest:
Final Thoughts and Clinical Trials in NMIBCExperts share their concluding thoughts on the recent progress and future outlook for the treatment of non–muscle-invasive bladder cancer (NMIBC).
Latest:
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy“Our findings support that that we do not drop the label of cancer from grade group 1 nomenclature," says Jim C. Hu, MD, MPH.
Latest:
Joy Maulik, CRNP, on the importance of genetic testing in prostate cancer“I truly think genetic testing should be incorporated as a part of daily care in prostate cancer,” says Joy Maulik, CRNP.
Latest:
Real-time IRP monitoring may redefine safety and scope of flexible ureteroscopyProfessor Andreas Skolarikos shares his experience with the LithoVue Elite System.
Latest:
Scott Tagawa, MD, highlights phase 3 trial of 177Lu-TLX591 in mCRPCProstACT GLOBAL is assessing the safety and efficacy of 177Lu-TLX591 plus SOC vs SOC alone in patients with mCRPC.
Latest:
Is your practice equipped to battle ransomware attacks?3 steps to protect your practice from ransomware.
Latest:
Frontline masitinib combo delays progression in mCRPC with low metastatic involvementAdding the investigational agent masitinib to standard frontline docetaxel significantly reduced the risk of disease progression or death in men with metastatic castration-resistant prostate cancer and baseline alkaline phosphatase levels (ALP) of 250 IU/mL or less.
